Niraparib

则乐(Zejula)

Zai Lab / GSK · Class: PARP

A PARP inhibitor pill usable for maintenance regardless of BRCA status.

At a glance

China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2019); NRDL (2020)

What it treats

Ovarian cancer maintenance after platinum chemotherapy.

← All drugs

Sources & verification

Overall status: Pending verification. Last verified: 2026-09-08.

No independent source is currently on file. We have not independently verified this information.

Reader discussion

Public comments about Niraparib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.